Trial · NCT07897890
Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care
NCT07897890, Not applicable, Completed, Indiana University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care. Trials, record NCT07897890. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897890
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Testing Health-Related Interventions: Voices of Equity Needed to Overcome Weight-bias in Obesity-Cancer Care
- NCT number
- NCT07897890
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 12 participants, actual
- Lead sponsor
- Indiana University
- Conditions
- Obesity & Overweight, Breast Cancer
- Interventions
- THRIVE NOW
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants enrolled and retained | End of treatment at 8 weeks after baseline | The percentage of breast cancer survivors who enrolled in the study and were retained at post-treatment (0-100%; higher percentage = more retained) |
| Primary | Attendance rates (Acceptability) | Weekly attendance at each of the 8 THRIVE NOW sessions from baseline to last session | Percentage of sessions that participants attended in person and/or made-up (0-100%; higher percentage = higher attendance) |
| Primary | Acceptability (Program Evaluation) | End of treatment at 8 weeks after baseline | Scores on the Treatment Acceptability/Adherence Scale (TAAS) (10-70; higher scores = greater acceptability/adherence ratings) |
| Secondary | Fat mass | From baseline to the end of treatment at 8 weeks | Change in fat mass (kg) from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Secondary | Cancer-related symptom (fatigue severity) | From baseline to the end of treatment at 8 weeks | Fatigue severity using the Fatigue Symptom Inventory (FSI) (0-10; with higher scores = more severe fatigue) |
| Secondary | Cancer-related symptom (fatigue interference) | From baseline to the end of treatment at 8 weeks | Fatigue interference using the Fatigue Symptom Inventory (FSI) (0-70; with higher scores = more fatigue interference) |
| Secondary | Cancer-related symptoms (pain severity) | From baseline to the end of treatment at 8 weeks | Pain severity assessed using the PROMIS Pain Intensity Short Form (T-score 50 +/- 10; higher scores = greater pain severity) |
| Secondary | Cancer-related symptoms (pain interference) | From baseline to the end of treatment at 8 weeks | Pain interference assessed using the PROMIS Pain Interference Short Form (T-score 50 +/- 10; higher scores = greater pain interference) |
| Secondary | Processed Food Consumption | From baseline to the end of treatment at 8 weeks | Processed food consumption measure using the Screening Questionnaire of Highly Processed Food Consumption (sQ-HPF; 0-14; greater scores = higher processed food consumption) |
| Secondary | Physical Activity | From baseline to the end of treatment at 8 weeks | MET-Minutes from the Self-reported International Physical Activity Questionnaire (IPAQ; MET/min; higher scores = more physical activity) |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40843140 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897890
GET https://conductscience.org/api/trials/v1/NCT07897890/registered?page=2